A series of novel spiroether-based neurokinin-1 (NK(1)) antagonists is described. The effect of modifications to the spiroether ring and aromatic substituents are discussed, leading to the identification of compounds with high affinity and excellent CNS penetration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0960-894x(02)00509-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
NK1 receptor blockade disrupts microtumor growth and aggregation in a three-dimensional murine breast cancer model.
Neuropeptides
October 2024
Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Several data indicate that Substance P (SP) neurokinin type 1 receptor (NK1R) is at the center of the interaction between cancer cells and peripheral sensory neurons. Selecting the appropriate cancer cell line and its susceptibility to being modulated by NK1 antagonists are critical to studying this complex interaction. In the current study, we have focused on this selection by comparing several aspects of the triple-negative breast cancer (TNBC) cell line (MDA-MB-231) with a modified murine cell line (E0771), both expressing luciferase.
View Article and Find Full Text PDFClinical benefits of adding olanzapine to 5-HT receptor antagonist, NK receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.
Int J Clin Oncol
November 2024
Department of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawahara‑Cho, Sakyo-ku, Shogoin, Kyoto, 606‑8507, Japan.
Article Synopsis
- Olanzapine is an atypical antipsychotic that helps prevent nausea and vomiting, particularly after highly emetogenic chemotherapy (HEC), but it can cause side effects like hyperglycemia and drowsiness.
- A systematic review and meta-analysis assessed the effectiveness of olanzapine combined with standard triplet antiemetic therapy compared to triplet therapy alone, focusing on outcomes like nausea control and adverse effects.
- Results showed that adding olanzapine significantly improved nausea and vomiting prevention in both acute and delayed phases with minimal adverse effects, indicating it can be beneficial for patients undergoing HEC.
Antiemetic medications for preventing chemotherapy-induced nausea and vomiting in children: a systematic review and Bayesian network meta-analysis.
Support Care Cancer
October 2024
Centre for Reviews and Dissemination, University of York, Heslington, York, YO10 5DD, UK.
Article Synopsis
- * A systematic review and Bayesian network meta-analysis (NMA) were conducted to compare multiple antiemetic treatments, analyzing data from 16 randomized controlled trials involving over 3,000 patients.
- * Results indicate that NK1 antagonists combined with ondansetron are the most effective option for preventing CINV in children, particularly when given with dexamethasone, while olanzapine also shows significant benefits when added to certain regimens.
Corticosteroid therapy in older adults with cancer: Expert recommendations from a task force of the International Society of Geriatric Oncology.
J Geriatr Oncol
October 2024
Clinic of Oncology, HFR Fribourg Hospital, Fribourg, Switzerland. Electronic address:
Corticosteroids are used frequently in oncology and many patients require short- or long-term corticosteroid therapy. General clinical guidelines and recommendations exist on the use of corticosteroids; however, evidence is lacking for recommendations on their appropriate use in older adult with cancer. Treatment of chemotherapy-induced nausea and vomiting (CINV) has dramatically improved over the last decade with 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists and neurokinin-1 (NK-1) receptor antagonists or a combination of both.
View Article and Find Full Text PDFIncidence of post-operative nausea and vomiting after endoscopic bariatric and metabolic therapy procedures and the role of neurokinin-1 receptor antagonists: a retrospective cohort study.
Surg Endosc
December 2024
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, 200 1St Street SW, Rochester, MN, 55905, USA.
Article Synopsis
- The study investigates the incidence of postoperative nausea and vomiting (PONV) in patients who underwent endoscopic bariatric and metabolic therapies (EBMT), focusing on the impact of neurokinin-1 receptor (NK-1) antagonists on PONV rates.
- Out of 404 patients, 62.6% experienced PONV, with significant differences in rates between those who received NK-1 antagonists (35%) and those who did not (74%).
- The findings suggest that using NK-1 antagonists as part of a comprehensive approach to prevent PONV significantly lowers the likelihood of this adverse event in patients recovering from EBMT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!